Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5918_Библиотеки_им_академика_М_И_Перельмана
.pdf
Chapter 19
https://t.me/med1917
Articial Intelligence: AMajor Landmark
intheNovel Drug Discovery Pathway
fortheRemarkable Advancement
intheHealthcare System
RabinDebnath, AbuMdAshifIkbal, AnkitaChoudhury,
SubhashC.Mandal, andParthaPalit
Abstract The healthcare industry is entering a new era of efciency and personali-
sation because of the integration of articial intelligence (AI), which has completely
transformed medical research and development. With the use of machine learning
and deep learning algorithms, articial intelligence has had a particularly signicant
impact on drug discovery, simplifying the design and optimisation of novel molecules. Articial intelligence (AI) optimises research designs for clinical trials,
reducing procedures and increasing data analysis efciency. Dynamic treatments
and customised patient care are guaranteed by AI-powered real-time monitoring.
Multidisciplinary innovation in medicine development is fuelled by the cooperative
efforts of data analysts, physicians, and subject matter experts. AI optimises pharmaceutical resource potential and supports sustainable practices by accelerating
drug discovery procedures. Personalised medicine is made possible by biomarker
discovery, which is powered by AI and allows for the identication of critical indicators for disease states and treatment responses. Articial intelligence (AI) in clinical trials leads to faster and more dependable therapeutic outcomes by streamlining
designs, identifying patient subpopulations, and improving data processing efciency. Articial intelligence-driven surveillance enables instantaneous monitoring,
R. Debnath
ISF College of Pharmacy, Ghall Kalan, Punjab, India
A. M. A. Ikbal · P. Palit (*)
Department of Pharmaceutical Sciences, Drug Discovery Research Laboratory, Assam
University (A Central University), Silchar, India
A. Choudhury
Silchar Medical College and Hospital, College of Pharmacy, Silchar, India
S. C. Mandal
Pharmacognosy & Phytotherapy Research Laboratory, Division of Pharmacognosy,
Department of Pharmaceutical Technology, Faculty of Engineering & Technology, Jadavpur
University, Kolkata, India
Ltd. 2024
S. Bose et al. (eds.), Concepts in Pharmaceutical Biotechnology and Drug
Development, Interdisciplinary Biotechnological Advances,
https://doi.org/10.1007/978-981-97-1148-2_19
413© The Author(s), under exclusive license to Springer Nature Singapore Pte
414
https://t.me/med1917
guaranteeing adaptable and customised patient interventions. A exible and patientcentred healthcare system is made possible by AI systems’ continuous learning
capabilities, which adapt based on actual patient data. Overall, AI’s transdisciplinary
inuence drives medication research and discovery towards more precise, effective,
and personalised healthcare solutions, with the potential to yield ground-breaking
discoveries that will benet people all over the world.
Keywords Articial intelligence (AI) · Drug discovery · Personalised medicine ·
Clinical trials · Healthcare efciency
R. Debnath et al.
19.1 Introduction
19.1.1 Natural Language Processing, Deep Learning,
andMachine Learning
Drug discovery technologies are being revolutionised by the strong tools of natural
language processing (NLP), deep learning, and machine learning, which are bringing new speed and efciency to the process. An enormous amount of biological data
is being analysed, intricate patterns are being determined, and the process of nding
new drug candidates is being accelerated considerably with the help of articial
intelligence (AI) (Gupta etal. 2021). With new approaches to persistent problems,
the combination of articial intelligence and drug discovery has enormous potential
for the pharmaceutical sector. The interaction of computers with human language is
the focus of the AI subeld of natural language processing (Jiménez-Luna etal.
2021). Natural language processing (NLP) plays a key role in drug development by
helping to extract useful information from a wide range of sources, including patents, trials, and scholarly publications. It helps scholars nd undiscovered connections and remain up to date on new advancements. The time and effort needed for
literature mining can be greatly reduced by using natural language processing
(NLP) techniques to navigate through large datasets and nd pertinent molecular
relationships, disease pathways, and possible therapeutic targets (Wang and Lin
2023). A kind of machine learning called deep learning has shown a remarkable
ability to handle complex biological data. Conventional approaches are insufcient
for thorough analysis due to the intricacy of molecular interactions and the volume
of omics data. Deep learning models especially neural networks are very good at
nding hidden correlations, identifying complex patterns in datasets, and forecasting the behaviours of molecules (Mahmud etal. 2021). These powers are used in
drug development for tasks including molecular structure optimisation, drug-drug
interaction prediction, and virtual screening. Because deep learning models can
identify minute details in biological data, researchers will be better equipped to
decide on the safety and possible effectiveness of drug candidates. Drug discovery
can be accomplished with a variety of tools and approaches provided by machine
learning, the larger parent eld of deep learning (Tiwari and Singh 2022). Machine
learning algorithms are useful in identifying possible drug candidates and
19 Articial Intelligence: A Major Landmark in the Novel Drug Discovery Pathway…
https://t.me/med1917
415
streamlining drug development procedures through various applications such as
predictive modelling and clustering analysis. In one noteworthy application,
machine learning models are used to identify possible therapeutic targets linked to
certain diseases by analysing a variety of biological parameters (Hussain et al.
2021). This focused strategy reduces resource waste and maximises performance by
optimising the drug discovery process. The use of AI in drug discovery has sped up
the entire drug development lifecycle, resulting in the creation of novel platforms.
In order to speed up the diagnosis and molecular understanding of diseases,
AI-driven platforms, for example, can make it easier to identify biomarkers unique
to each disease. Using this information in conjunction with sophisticated analytics
makes it possible to identify potential drug targets and create more accurate and
successful therapeutic interventions (Dara etal. 2022). Articial intelligence has
been shown to be quite helpful in improving patient recruitment and clinical trial
design. The effectiveness and success rates of clinical trials can be increased by
using machine learning algorithms to evaluate a variety of datasets and identify
patient groups that are most likely to respond favourably to a specic treatment.
This focused strategy lowers the time and expense of medication research while
simultaneously raising the possibility of successful medicines being introduced to
the market (Harrer etal. 2019).
Pharmaceutical research is changing as a result of the integration of deep learning, machine learning, and natural language processing in AI-powered drug discovery technologies. Not only are these technologies speeding up procedures, but they
are also radically altering how scientists approach drug development (Liu etal.
2021). AI’s uses in drug development are probably going to get even more advanced
as it develops, opening the door for a new era of precision medicine and tailored
therapeutic interventions. AI and drug discovery working together could speed up
the creation of ground-breaking therapies, ultimately leading to better patient outcomes and a revolution in the pharmaceutical sector (Gennatas and Chen 2021). The
combination of deep learning, machine learning, and natural language processing
(NLP) in drug discovery technologies is not only revolutionising research procedures but also solving major issues that have long plagued the pharmaceutical sector. The massive amount of biomedical literature, which is growing rapidly every
year, has been one of the major challenges in drug development. NLP is revolutionary because it can understand large text libraries and extract valuable information
from them. It helps scientists stay up to date on the most recent discoveries in science, determine possible therapeutic targets, and evaluate hypotheses more quickly
(Öztürk etal. 2020).
NLP is essential not only for literature mining but also for knowledge representation and extraction from unstructured data. NLP makes it easier to integrate textual
data by converting it into structured representations. NLP is important for knowledge representation and extraction from unstructured data, in addition to literature
mining. Natural language processing (NLP) enables the integration of disparate
data sources by converting textual content into structured representations (Baviskar
etal. 2021). This integration enables researchers to nd connections between genes,
proteins, and pathways that may have gone unnoticed using more conventional
techniques, which is crucial for a comprehensive knowledge of complex biological
416
https://t.me/med1917
systems. Proteomics, genomics, and other omics domains possess complex and
high-dimensional data, which is where deep learning, especially with neural networks, shines. Deep learning models are well suited for applications such as medication repurposing and chemical structure prediction because they can learn
hierarchical representations of data. Deep learning models have the capability to
analyse the three-dimensional structures of compounds and predict their biological
activities. This makes it possible to identify medications that are currently on the
market and potentially repurpose them for new uses (Sidak etal. 2022).
R. Debnath et al.
19.1.2 Examining Enormous Databases toIdentify Potential
Drug Candidates
One of the most important areas of drug discovery technologies is the analysis of
massive databases to nd possible drug candidates. Articial intelligence (AI) is a
key player in this revolutionary process (Paul etal. 2021). Modern biological data
are so large and complicated that navigating them and extracting useful information
require sophisticated computational techniques. AI, along with its subelds such as
deep learning and machine learning, is becoming more and more the driving force
that drives the identication and validation of possible therapeutic options. The
time-consuming and resource-intensive process of searching through enormous
chemical libraries for possible compounds has been one of the main obstacles in
traditional drug discovery (Górriz etal. 2020). AI solutions improve and automate
the screening process in order to overcome this difculty. Machine learning algorithms have the ability to forecast the possibility of a novel chemical interacting
with certain biological targets after being trained on large datasets of documented
drug-target interactions. The early phases of drug development can be greatly accelerated by using this prediction power to help researchers choose which compounds
they should investigate further. Large-scale biological dataset analysis benets
greatly from deep learning’s capacity to identify intricate patterns in data (Abbasi
etal. 2021). Deep learning models, a subset of articial neural networks, excel at
extracting intricate patterns from vast datasets for tasks like image recognition and
natural language processing. In biology, they adeptly learn from raw proteomic,
metabolomic, and genomic data to predict protein interactions, metabolic outcomes,
gene functions, and disease associations. This skill is crucial for locating possible
medication candidates with particular target characteristics, allowing for a more
focused and effective drug development procedure. The extraction of information
from scientic publications, patents, and clinical trial reports also heavily relies on
natural language processing, or NLP (Sen etal. 2021). Natural language processing
(NLP) helps identify possible therapeutic targets, comprehend disease pathways,
and validate current theories by drawing insights from this enormous body of
knowledge. Scientists may make well-informed decisions on which compounds to
pursue by utilising NLP’s integration with other AI technologies, which guarantees
a thorough study of all accessible data. Through the use of these technologies,
AI-driven drug discovery platforms develop a comprehensive method for
19 Articial Intelligence: A Major Landmark in the Novel Drug Discovery Pathway…
https://t.me/med1917
identifying potential candidates (Demner-Fushman etal. 2021). To give a comprehensive image of possible medication candidates, these platforms combine information from multiple sources, such as clinical data, experimental results, and literature.
These tools help scientists decide which compounds have the best chance of making
it through the drug development pipeline by automating the study of various data
types. In addition, articial intelligence technologies support the idea of drug repurposing, the process of nding new therapeutic indications for already-approved
medications. Machine learning algorithms can reveal previously unknown relationships between drugs and disorders by examining big datasets that contain clinical
outcomes, molecular proles, and drug interactions. This could result in the identication of innovative uses for already-approved pharmaceuticals. The hazards
involved in creating completely new medications are decreased by this method,
which also speeds up the drug development process by utilising the safety proles
of existing molecules (Tripathi etal. 2022).
The use of AI technologies is revolutionising the process of searching through
massive databases for possible medication candidates. Together, these technologies
enable researchers to more effectively traverse the huge terrain of biological data.
Machine learning predicts interactions, deep learning reveals intricate correlations
in large datasets, and natural language processing extracts knowledge from extensive textual sources. AI is expected to play a bigger part in drug development as
technology develops, perhaps leading to more focused, effective, and creative methods for nding the next wave of therapeutic interventions. AI and drug development
are working together to create a synergistic effect that will lead to faster, more
accurate, and more informed identication of possible therapeutic candidates in the
future (Husnain etal. 2023).
417
19.1.3 Quickly Identifying Drug-Target Interactions
andBiomarkers toExpedite Preclinical Research
To accelerate preclinical research, it is necessary to quickly identify drug-target
interactions and biomarkers. Articial intelligence (AI) is one such advanced technology that can be used to precisely and quickly identify biomarkers linked to particular biological processes or disease states, as well as possible interactions between
drug compounds and molecular targets. The quick identication of drug-target
interactions and biomarkers is an essential phase in the changing landscape of drug
discovery that greatly affects preclinical research efciency (Boniolo etal. 2021).
The process of identifying potential candidates and biomarkers is being revolutionised with unprecedented speed and precision through the utilisation of articial
intelligence (AI), specically through the application of advanced technologies
such as machine learning, deep learning, and natural language processing (NLP).
As a result of their training on large datasets with data regarding established drugtarget interactions, machine learning models have become extremely effective at
forecasting novel interactions. These models have the ability to examine intricate
418
https://t.me/med1917
R. Debnath et al.
patterns in biological data and identify possible connections between medicinal
substances and particular molecular targets (Tor etal. 2020). AI-driven algorithms
can quickly go through massive databases to identify possible candidates for more
research, greatly cutting down on the amount of time needed to complete the task.
By nding and validating potential therapeutic candidates and relevant biomarkers
more quickly, the aim is to accelerate the preclinical research stage of drug discovery.
• Drug Interactions with Targets:
– Traditional Challenges: Traditionally, selecting the appropriate molecular tar-
gets for medicinal substances has required rigorous screening procedures and
substantial experimentation.
– Articial Intelligence Solutions: By analysing vast datasets, which include
details on established drug-target interactions, machine learning and deep
learning algorithms can more accurately forecast possible interactions. These
algorithms identify trends in biological data and identify pharmacological
candidates that have a higher probability of interacting with particular molecular targets (Selvaraj etal. 2021).
• Identication of Biomarkers:
– Traditional Challenges: Determining biomarkers linked to certain biological
processes or disorders frequently necessitates extensive and time-consuming
investigation.
– AI Remedies: Potential biomarkers can be quickly identied using machine
learning models that have been trained on a variety of datasets, including
genomes, proteomics, and clinical data. These models identify indicators that
might be connected to specic circumstances by examining patterns and correlations in the data. This expedites the process of identifying biomarkers,
hence facilitating prompt conrmation in preclinical investigations (Sun
etal. 2023).
• Accelerated Preclinical Research:
– Conventional Timelines: Before moving on to clinical trials, preclinical
research usually entails a number of tests and validations to guarantee the
efcacy and safety of possible medication candidates.
– AI Impact: AI accelerates preclinical research by rapidly discovering bio-
markers and drug-target interactions. The time and resources needed for preliminary investigations can be decreased by researchers concentrating their
efforts on candidates and biomarkers with better prediction success rates
(Zhavoronkov etal. 2019).
• Potential for Personalised Medicine:
– Conventional Approaches: Creating treatments based on a one-size-ts-all
concept may cause patients’ responses to differ from one another.
– AI Developments: Quick biomarker identication enables more individual-
ised treatment. AI systems have the capacity to evaluate patient-specic data
19 Articial Intelligence: A Major Landmark in the Novel Drug Discovery Pathway…
https://t.me/med1917
in order to nd distinct biomarkers, opening the door for customised treatments
based on personal traits. This lowers the possibility of side effects while
simultaneously increasing therapeutic efcacy (Schork 2019).
• AI-Powered Systems: Integration of Technologies: AI-driven platforms integrate
machine learning, deep learning, and natural language processing (NLP) to con-
duct comprehensive analyses of a variety of data sources.
• Automation and Efciency: These platforms automate the analysis of large data-
sets, giving researchers a comprehensive understanding of possible drug-target
interactions and biomarkers. Automation improves efciency and facilitates
data-driven decision-making (Evangelista 2020).
• To sum up, using AI to rapidly identify drug-target interactions and biomarkers
is a game-changing strategy in drug discovery as it speeds up preclinical research,
improves the identication of promising candidates, and has the potential to
usher in a new era of personalised medicine by customising treatments for each
patient.
419
19.2 Using AI toRepurpose Drugs
The eld of pharmaceutical research and development has seen a signicant transformation in recent years due to the growing inuence of articial intelligence (AI)
on drug discovery. One important part of this revolution is repurposing existing
drugs for novel medicinal purposes. This section examines the several applications
of articial intelligence (AI) in the investigation of already licenced drugs and their
potential across a range of therapeutic areas (Mak and Pichika 2019). The investigation consists of three primary parts: III.A. examining already-approved medications
for potential novel therapeutic applications; III.B. analysing pharmacological interactions and biological networks in silico; and III.C. examining medications that are
well designed and optimised for a variety of functions.
19.2.1 Investigating Previously Authorised Drugs forPotential
Novel Therapeutic Uses
“Repurposing” medicines refers to investigating uses for well-known pharmacological compounds outside of their original intended purposes (Pushpakom etal.
2019). This strategy relies heavily on AI since it can sift through massive datasets
and identify candidates who could benet from repositioning. Using complex algorithms and machine learning models, the system evaluates data from a range of
sources, including genetic databases, clinical trial data, and biological literature (Vo
etal. 2019).
420
https://t.me/med1917
By utilising articial intelligence (AI) to thoroughly evaluate the safety and efcacy characteristics of presently marketed drugs, researchers can identify promising
candidates for novel therapeutic indications. This tactic reduces the amount of time
needed for drug development while also utilising the wealth of information found in
approved medications. For example, a drug that initially showed promise in treating
one condition may have properties that make it suitable for treating a completely
different medical condition (Vatansever etal. 2021).
Furthermore, using AI to repurpose medications increases the chance of successful clinical studies. Predictive modelling and data analytics allow researchers to
identify pharmacological candidates with the highest chance of success, which
helps them prioritise their efforts and save overall drug development costs.
When evaluating already-approved pharmaceuticals for novel therapeutic uses, a
detailed analysis of their recognised pharmacological properties is required.
Articial intelligence algorithms search through massive databases containing
information on drug interactions, side effects, and outcomes of clinical trials. By
identifying patterns and connections within this massive information, articial
intelligence (AI) enables the discovery of new candidates that may demonstrate
efcacy against diseases outside of their initial indications. This data-driven
approach expedites the discovery of new therapeutic applications and provides a
workable replacement for traditional drug development (Bobo etal. 2016).
In the area of previously approved medication investigations, articial intelligence’s
ability to analyse real patient data and electronic health records contributes to our growing knowledge of drug reactions. By taking into consideration, variables such as patient
demographics, comorbidities, and treatment outcomes, AI assists in identifying certain
patient populations that might benet most from the repurposed drugs (Ahmed etal.
2022). By ensuring that repositioned pharmaceuticals are not only effective but also
tailored to the individual needs of the individuals they are meant to treat, this patientcentred approach increases the accuracy of treatment programmes.
R. Debnath et al.
19.2.2 Biological Networks andPharmacological Interactions
Investigated InSilico
The phrase “in silico” describes computational methods based on computers that
have been shown to be crucial for the repurposing of medications. AI-driven biological network and pharmacological interaction analysis can help us better understand the complex relationships that exist between drugs, biological processes, and
diseases (Russo etal. 2020).
Biological networks are challenging to manually understand because they entail
intricate relationships between genes, proteins, and other components. AI system’s
deep learning models in particular are highly adept at navigating these intricate
networks and identifying potential sites for pharmaceutical repurposing interventions. Knowing more about the underlying biology allows researchers to more precisely and effectively move drugs to target specic nodes in the network.
19 Articial Intelligence: A Major Landmark in the Novel Drug Discovery Pathway…
https://t.me/med1917
Moreover, AI enables the speed and volume of pharmacological interaction analysis that are not achievable with traditional methods. It is feasible to identify candidates that may exhibit the requisite pharmacological activity by virtually screening
drug libraries against specic targets relevant to disease states. This in silico screening signicantly expedites the search for new treatments by selecting drugs based
on a reason.
In silico research of biological networks and pharmacological interactions is the
application of articial intelligence (AI) to model and simulate complex biological
processes (Davahli etal. 2021). Articial intelligence algorithms have exceptional
abilities to decipher the intricate web of connections between biological pathways,
offering valuable perspectives on potential targets for pharmaceutical intervention.
Researchers may theoretically screen treatment possibilities against specic molecular targets, allowing them to rank compounds with the best possibility of success.
By accelerating the discovery of prospective treatment candidates and providing a
sound basis for experimental validation, this computational technique maximises
the use of resources in the drug development pipeline.
In in silico studies of biological networks and pharmacological interactions,
AI-driven analyses also identify potential side effects and drug-drug interactions.
Articial intelligence (AI) uses a model of biological systems’ behaviour to identify
potential safety risks in pharmaceuticals (Selvaraj etal. 2021). This makes it possible for researchers to foresee potential issues that may arise during clinical trials.
This proactive strategy streamlines the medication development process, improves
the overall safety and efcacy of repurposed pharmaceuticals, and increases the
likelihood of positive outcomes in a range of patient populations.
421
19.2.3 Drugs that Are Effectively Designed andOptimised
foraVariety ofUses
Optimising drug design is essential for successful repurposing, and articial intelligence (AI) brings a fresh dimension to this endeavour. Through sophisticated
computational methodologies, articial intelligence (AI) aids in the design of pharmaceuticals with increased therapeutic properties for new purposes in addition to
their original effectiveness for their original indications (Fischer etal. 2019).
Machine learning algorithms have the capability to predict the most effective
chemical modications to alter the specicity or boost the efciency of medicine,
thanks to training from vast databases of molecular structures and the biological
activities associated with them. A technique known as “de novo drug design” makes
it possible to create analogues or derivatives of existing drugs that have superior
pharmacological properties (Yang etal. 2019).
Not only are molecular structures but also dosing schedules and treatment
approaches susceptible to AI-driven optimisation. By assessing clinical results and
actual patient data, AI is able to offer personalised treatment plans that enhance
therapeutic effectiveness and reduce side effects. This systematic approach increases
422
https://t.me/med1917
the overall effectiveness of drug repurposing by tailoring therapies to the unique
characteristics of each patient.
Using AI-driven design, drug optimisation for a variety of therapeutic purposes
is a challenging task. Articial intelligence (AI) systems use molecular structures to
predict chemical changes that could increase or decrease a drug’s effectiveness
(Tiwari etal. 2023). Another use of predictive modelling is dosage optimisation,
where AI prescribes customised dose regimens based on factors such as therapy
response, genetic variations, and patient demographics. By tailoring drug design to
specic patient characteristics, AI ushers in a new era of precision medicine in the
area of medication repurposing. This maximises therapeutic efcacy and reduces
the possibility of adverse reactions (Zhou etal. 2020).
AI affects the creation of combination therapies and the optimisation of drugs for
a range of uses. By analysing the synergistic effects of many drugs in a therapeutic
environment, AI develops strategies to mix pharmaceuticals in ways that maximise
benets and reduce bad effects. This technique not only broadens the therapeutic
window for drugs that are already on the market, but it also opens doors for innovative therapeutic strategies. AI also simplies the process of looking into medication
repurposing in the context of recently identied illnesses, rapidly altering existing
medications to satisfy evolving healthcare requirements and providing timely
answers to novel health hazards (Sharma etal. 2022).
In summary, the use of AI in pharmaceutical repurposing represents a major breakthrough in the hunt for novel therapeutic strategies. Enhancing health care and expediting drug discovery are interdependent. Methodical review of approved drugs,
biological network analysis, and AI-optimised drug design are required. As technology progresses, how AI uses previously approved drugs to uncover new therapeutic
uses will likely have a signicant impact on how medicine evolves in the future.
R. Debnath et al.
19.3 Clinical Trials andAI’s Impact
Articial intelligence (AI) has brought forth a new era in drug research and signicantly impacted clinical trials. This section examines the ways in which articial
intelligence (AI) is profoundly altering the eld of clinical trials. It concentrates on
four main points: IV.A. better clinical trial design; IV.B. more patient acquisition;
IV.C. patient reaction predicting to boost trial success rates; and IV.D. cutting down
on the length of time and expense associated with medication development.
19.3.1 Improved Design ofClinical Trials
The effectiveness of clinical trials is largely dependent on their design, and articial
intelligence (AI) has emerged as a potent tool for expediting this process. Machine
learning algorithms, trained on extensive datasets encompassing a range of patient
groups and treatment results, facilitate the identication of relevant biomarkers and
Соседние файлы в папке Библиотека им академика М.И. Перельмана